Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.79 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | BCHE | P06276 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.71 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.67 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.67 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laudanosine SCHEMBL30816021 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL466529 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL29822950 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL6130845 | 1.00 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL11398962 | 0.96 | LMNA (0.93) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21346112 | 0.96 | LMNA (0.93) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL11398960 | 0.96 | LMNA (0.93) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21346139 | 0.95 | LMNA (0.90) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21346180 | 0.95 | LMNA (0.90) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Dimethylgrisabine SCHEMBL30735570 | 0.92 | LMNA (0.84) | LMNAKDM4EALDH1A1HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| EP-4355423-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | Indiana University Research and Technology Corporation (US) | 2024-04-24 | — | — | EP | claimed |
| EP-4289959-A1 | COMPOSITIONS AND METHODS FOR MAKING (R)-RETICULINE AND PRECURSORS THEREOF | Antheia, Inc. (US) | 2023-12-13 | — | — | EP | claimed |
| CN-111909089-B | Preparation method of mikui ammonium chloride reference substance | 广东嘉博制药有限公司 | 2023-04-14 | — | — | CN | claimed |
| US-11542481-B2 | Morphinan N-demethylase isolated from the methylobacterium thebainfresser and methods of use thereof | DONALD DANFORTH PLANT SCIENCE CENTER (US) | 2023-01-03 | — | — | US | claimed |
| WO-2022266407-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220403469-A1 | Precision Medicine for Schizophrenia and Psychotic Disorders: Objective Assessment, Risk Prediction, Pharmacogenomics, and Repurposed Drugs | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-12-22 | — | — | US | claimed |
| WO-2022150380-A1 | ALKALOID PRODUCING OXIDASES AND CARBOXY-LYASES AND METHODS OF USE | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2022-07-14 | — | — | WO | claimed |
| EP-3923962-A2 | GENE NETWORKS THAT MEDIATE REMYELINATION OF THE HUMAN BRAIN | University of Rochester (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2020167822-A2 | GENE NETWORKS THAT MEDIATE REMYELINATION OF THE HUMAN BRAIN | UNIVERSITY OF ROCHESTER (US) | 2020-08-20 | — | — | WO | claimed |
| EP-1613271-A2 | COMPUTER-BASED MODEL FOR IDENTIFICATION AND CHARACTERIZATION OF NON-COMPETITIVE INHIBITORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND RELATED LIGAND-GATED ION CHANNEL RECEPTORS | The Government of the United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2005053382-A1 | MODULATION OF CYTOCHROME P-450 REDUCTASE ACTIVITY IN POPPY PLANTS | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 2005-06-16 | — | — | WO | claimed |
| WO-2004091492-A2 | COMPUTER-BASED MODEL FOR IDENTIFICATION AND CHARACTERIZATION OF NON-COMPETITIVE INHIBITORS OF NICOTINIC ACETYLCHOLINE RECEPTORS AND RELATED LIGAND-GATED ION CHANNEL RECEPTORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040204862-A1 | Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF, THE | 2004-10-14 | — | — | US | claimed |
| CN-1117864-C | Prodn. of gamma linolenic acid by a | RHONE POULENC AGROCHIMIE (FR) | 2003-08-13 | — | — | CN | claimed |
| US-20030083485-A1 | Nucleotide sequences coding polypeptide for use the treament of cardiovascular disorders | PFIZER INC. | 2003-05-01 | — | — | US | claimed |
| US-20020147175-A1 | Synergistic ECTA compositions | NEWBIOTICS, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002039952-A2 | SYNERGISTIC ECTA COMPOSITIONS | NEWBIOTICS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| CN-1177379-A | Prodn. of gamma linolenic acid by a | RHONE POULENC AGROCHIMIE (FR) | 1998-03-25 | — | — | CN | claimed |
| CN-1072722-A | Production of gamma linolenic acid using delta 6-desaturase | RHONE POULENC AGROCHIMIE (FR) | 1993-06-02 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147175-A1 | Synergistic ECTA compositions | ENTPD1, ENTPD2, ENPP1 | LMNA 1897/4885KDM4E 4552/4885ALDH1A1 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.